TG Therapeutics Inc (TGTX)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	329,004	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152
Total assets	US$ in thousands	577,690	586,014	401,207	373,323	329,587	331,067	220,854	197,358	193,572	217,891	251,666	303,028	379,629	409,687	481,400	548,699	625,642	273,856	294,621	101,849
Total asset turnover		0.57	0.45	0.85	0.75	0.67	0.55	0.09	0.03	0.01	0.02	0.03	0.03	0.02	0.01	0.01	0.00	0.00	0.00	0.00	0.00

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $329,004K ÷ $577,690K
= 0.57

TG Therapeutics Inc's total asset turnover has shown significant fluctuations over the years. From March 31, 2020, to December 31, 2022, the total asset turnover remained consistently low at around 0.01 to 0.03, indicating that the company was not efficiently utilizing its assets to generate sales.

However, starting from March 31, 2023, there was a notable improvement in the total asset turnover ratio, increasing to 0.09 by June 30, 2023, and further to 0.67 by December 31, 2023. This sharp increase suggests that the company became more effective in generating sales revenue relative to its total assets during this period.

In the subsequent quarters, the total asset turnover continued to improve, reaching 0.85 by June 30, 2024. Despite a slight dip to 0.45 by September 30, 2024, the ratio remained relatively high compared to the previous years.

Overall, the upward trend in total asset turnover from 2023 to 2024 signifies an enhancement in efficiency and productivity in utilizing TG Therapeutics Inc's assets to drive sales.